SCHEMBL20554254

SCHEMBL20554254

[c]1noc(C2CCCCCCC2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
TDO2 P48775 2/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
CYP2C19 P33261 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
RAB9A P51151 5/20 0.34
NPC1 O15118 4/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
TP53 P04637 1/20 0.33
MAPK1 P28482 1/20 0.33
ALOX15B O15296 1/20 0.32
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CASP3 P42574 1/20 0.31
SENP7 Q9BQF6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20553989 1.00 ALDH1A1 (0.37) ALDH1A1TDO2LMNAPOLBCYP2C19
SCHEMBL3726887 1.00 ALDH1A1 (0.37) ALDH1A1TDO2LMNAPOLBCYP2C19
SCHEMBL3728561 0.98 TDO2 (0.35) ALDH1A1TDO2LMNAPOLBCYP2C19
SCHEMBL20554022 0.93
SCHEMBL20561676 0.76
SCHEMBL24623064 0.64 CYP2C19 (0.55) ALDH1A1LMNAPOLBCYP2C19NPC1
SCHEMBL9879297 0.63 ALDH1A1 (0.39) ALDH1A1LMNAPOLBCYP2C19CYP1A2
SCHEMBL14305108 0.62 CYP2C19 (0.53) ALDH1A1LMNAPOLBCYP2C19NPC1
SCHEMBL8628112 0.61 ALDH1A1 (0.37) ALDH1A1LMNAPOLBCYP2C19CYP1A2
SCHEMBL23624594 0.61 CASP3 (0.51) ALDH1A1POLBCYP2C19CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4023640-A1 PHENYLIMIDAZOLE COMPOUND Otsuka Pharmaceutical Factory, Inc. (JP) 2022-07-06 EP disclosed
CN-113200962-A Phenylimidazole compounds 株式会社大塚制药工场 2021-08-03 CN disclosed
CN-108430977-B Phenylimidazole compounds 株式会社大塚制药工场 2021-06-08 CN disclosed
US-10570117-B2 Phenylimidazole compound OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2020-02-25 US disclosed
US-20180354930-A1 PHENYLIMIDAZOLE COMPOUND OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2018-12-13 US disclosed
EP-3401310-A1 PHENYLIMIDAZOLE COMPOUND Otsuka Pharmaceutical Factory, Inc. (JP) 2018-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10570117-B2 Phenylimidazole compound LPL, PNLIP, LIPC ALDH1A1 263/4885TDO2 3504/4885LMNA 1063/4885
US-20180354930-A1 PHENYLIMIDAZOLE COMPOUND PNLIP, PLIN1, HDAC11 ALDH1A1 457/4885TDO2 4641/4885LMNA 3128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.